426 related articles for article (PubMed ID: 28848227)
1. Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation.
Chakraborty R; Muchtar E; Kumar SK; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Warsame R; Kourelis T; Gonsalves W; Gertz MA
Leukemia; 2018 Mar; 32(3):712-718. PubMed ID: 28848227
[TBL] [Abstract][Full Text] [Related]
2. Real world outcomes of lenalidomide or bortezomib maintenance in patients with multiple myeloma not undergoing stem cell transplantation.
Xu T; Yang Y; Li J; Xu J; Wang W; Wang Y; Maihemaiti A; Ren L; Lan T; Zhou C; Li P; Wang P; Liu P
Ann Hematol; 2023 May; 102(5):1171-1184. PubMed ID: 36882560
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma.
Sivaraj D; Green MM; Li Z; Sung AD; Sarantopoulos S; Kang Y; Long GD; Horwitz ME; Lopez RD; Sullivan KM; Rizzieri DA; Chao NJ; Gasparetto C
Biol Blood Marrow Transplant; 2017 Feb; 23(2):262-268. PubMed ID: 27856369
[TBL] [Abstract][Full Text] [Related]
4. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.
Stadtmauer EA; Pasquini MC; Blackwell B; Hari P; Bashey A; Devine S; Efebera Y; Ganguly S; Gasparetto C; Geller N; Horowitz MM; Koreth J; Knust K; Landau H; Brunstein C; McCarthy P; Nelson C; Qazilbash MH; Shah N; Vesole DH; Vij R; Vogl DT; Giralt S; Somlo G; Krishnan A
J Clin Oncol; 2019 Mar; 37(7):589-597. PubMed ID: 30653422
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma.
Pasvolsky O; Milton DR; Rauf M; Tanner MR; Bashir Q; Srour S; Tang G; Saini N; Ramdial J; Masood A; Nieto Y; Lee HC; Patel KK; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
Transplant Cell Ther; 2022 Nov; 28(11):752.e1-752.e6. PubMed ID: 35940528
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
7. Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response.
Mina R; Petrucci MT; Corradini P; Spada S; Patriarca F; Cerrato C; De Paoli L; Pescosta N; Ria R; Malfitano A; Musto P; Baldini L; Guglielmelli T; Gamberi B; Mannina D; Benevolo G; Zambello R; Falcone AP; Palumbo A; Nagler A; Calafiore V; Hájek R; Spencer A; Boccadoro M; Bringhen S
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):533-540. PubMed ID: 29910180
[TBL] [Abstract][Full Text] [Related]
8. Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial.
Goldschmidt H; Mai EK; Dürig J; Scheid C; Weisel KC; Kunz C; Bertsch U; Hielscher T; Merz M; Munder M; Lindemann HW; Hügle-Dörr B; Tichy D; Giesen N; Hose D; Seckinger A; Huhn S; Luntz S; Jauch A; Elmaagacli A; Rabold B; Fuhrmann S; Brossart P; Goerner M; Bernhard H; Hoffmann M; Hillengass J; Raab MS; Blau IW; Hänel M; Salwender HJ;
Leukemia; 2020 Jul; 34(7):1853-1865. PubMed ID: 32034285
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma.
Sidiqi MH; Aljama MA; Bin Riaz I; Dispenzieri A; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Hogan WJ; Rajkumar SV; Kumar SK; Gertz MA
Blood Cancer J; 2018 Nov; 8(11):106. PubMed ID: 30409963
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
Attal M; Lauwers-Cances V; Hulin C; Leleu X; Caillot D; Escoffre M; Arnulf B; Macro M; Belhadj K; Garderet L; Roussel M; Payen C; Mathiot C; Fermand JP; Meuleman N; Rollet S; Maglio ME; Zeytoonjian AA; Weller EA; Munshi N; Anderson KC; Richardson PG; Facon T; Avet-Loiseau H; Harousseau JL; Moreau P;
N Engl J Med; 2017 Apr; 376(14):1311-1320. PubMed ID: 28379796
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide maintenance post-transplantation in newly diagnosed multiple myeloma: real-world outcomes and costs.
Hari P; Ung B; Abouzaid S; Agarwal A; Parikh K
Future Oncol; 2019 Dec; 15(35):4045-4056. PubMed ID: 31625415
[No Abstract] [Full Text] [Related]
12. Autologous HSCT with novel agent-based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma.
Mori Y; Takizawa J; Katsuoka Y; Takezako N; Nagafuji K; Handa H; Kuroda J; Sunami K; Kamimura T; Ogawa R; Kikushige Y; Harada M; Akashi K; Miyamoto T;
Cancer Sci; 2024 Jun; 115(6):2002-2011. PubMed ID: 38498976
[TBL] [Abstract][Full Text] [Related]
13. Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma.
Sonneveld P; Dimopoulos MA; Beksac M; van der Holt B; Aquino S; Ludwig H; Zweegman S; Zander T; Zamagni E; Wester R; Hajek R; Pantani L; Dozza L; Gay F; Cafro A; De Rosa L; Morelli A; Gregersen H; Gulbrandsen N; Cornelisse P; Troia R; Oliva S; van de Velden V; Wu K; Ypma PF; Bos G; Levin MD; Pour L; Driessen C; Broijl A; Croockewit A; Minnema MC; Waage A; Hveding C; van de Donk NWCJ; Offidani M; Palumbo GA; Spencer A; Boccadoro M; Cavo M
J Clin Oncol; 2021 Nov; 39(32):3613-3622. PubMed ID: 34520219
[TBL] [Abstract][Full Text] [Related]
14. Post-transplant consolidation plus lenalidomide maintenance vs lenalidomide maintenance alone in multiple myeloma: A systematic review.
Al-Ani F; Louzada M
Eur J Haematol; 2017 Dec; 99(6):479-488. PubMed ID: 28885719
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of autologous stem cell transplantation after induction therapy with lenalidomide, bortezomib, and dexamethasone.
Arcani R; Venton G; Colle J; Suchon P; Ivanov V; Mercier C; Farnault L; Roche P; Lafage M; Brunet C; Azouza W; Pourroy B; Fanciullino R; Costello R
Eur J Haematol; 2019 Oct; 103(4):385-392. PubMed ID: 31319001
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial.
Jackson GH; Davies FE; Pawlyn C; Cairns DA; Striha A; Collett C; Waterhouse A; Jones JR; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Allotey D; Shafeek S; Jenner MW; Cook G; Russell NH; Kaiser MF; Drayson MT; Owen RG; Gregory WM; Morgan GJ; Clinical Studies Group UNHO
Haematologica; 2021 Jul; 106(7):1957-1967. PubMed ID: 32499244
[TBL] [Abstract][Full Text] [Related]
17. Autologous transplantation and maintenance therapy in multiple myeloma.
Palumbo A; Cavallo F; Gay F; Di Raimondo F; Ben Yehuda D; Petrucci MT; Pezzatti S; Caravita T; Cerrato C; Ribakovsky E; Genuardi M; Cafro A; Marcatti M; Catalano L; Offidani M; Carella AM; Zamagni E; Patriarca F; Musto P; Evangelista A; Ciccone G; Omedé P; Crippa C; Corradini P; Nagler A; Boccadoro M; Cavo M
N Engl J Med; 2014 Sep; 371(10):895-905. PubMed ID: 25184862
[TBL] [Abstract][Full Text] [Related]
18. Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma.
Arikian SR; Milentijevic D; Binder G; Gibson CJ; Hu XH; Nagarwala Y; Hussein M; Corvino FA; Surinach A; Usmani SZ
Curr Med Res Opin; 2015 Jun; 31(6):1105-15. PubMed ID: 25785551
[TBL] [Abstract][Full Text] [Related]
19. Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma.
Cornell RF; D'Souza A; Kassim AA; Costa LJ; Innis-Shelton RD; Zhang MJ; Huang J; Abidi M; Aiello J; Akpek G; Bashey A; Bashir Q; Cerny J; Comenzo R; Diaz MA; Freytes C; Gale RP; Ganguly S; Hamadani M; Hashmi S; Holmberg L; Hossain N; Kamble RT; Kharfan-Dabaja M; Kindwall-Keller T; Kyle R; Kumar S; Lazarus H; Lee C; Maiolino A; Marks DI; Meehan K; Mikhael J; Nath R; Nishihori T; Olsson RF; Ramanathan M; Saad A; Seo S; Usmani S; Vesole D; Vij R; Vogl D; Wirk BM; Yared J; Krishnan A; Mark T; Nieto Y; Hari P
Biol Blood Marrow Transplant; 2017 Feb; 23(2):269-277. PubMed ID: 27864161
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma.
Huang J; Phillips S; Byrne M; Chinratanalab W; Engelhardt BG; Goodman SA; Harrell SL; Jagasia M; Kassim A; Rawling KT; Savani BN; Sengsayadeth S; Cornell RF
Bone Marrow Transplant; 2018 Jun; 53(6):701-707. PubMed ID: 29703965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
